The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Relapse after HSCT 2021 | Improving virus-specific T-cell therapy
Susan Prockop, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses strategies aiming to improve the efficacy of viral-specific T-cells (VSTs). Research is currently being conducted to increase the immunogenicity of Epstein-Barr virus (EBV)-associated tumors by inducing expression of immunogenic proteins that VSTs can target. In addition, Dr Prockop describes how it is important to better understand the interaction between adoptively transferred T-cells and the recipient immune system to improve response durability. This interview took place at the 2021 Relapse After HSCT² Workshop in New York, NY.
